ESMO Immuno-Oncology 2025 | Expanding biomarkers beyond PD-L1 and TMB in melanoma
Inge Marie Svane, MD, PhD, Herlev University Hospital, Herlev, Denmark, gives an overview of the current state of biomarkers in melanoma. Whilst a few, such as PD-L1 and tumor mutational burden (TMB), are currently being used, additional biomarkers, including interferon gamma signatures and genomic profiles of the tumor microenvironment, will become important in predicting patient response to treatment. This interview took place at 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, I’m sure that we will see even more biomarkers. At this time point, it’s actually very few which are in clinical practice. For melanoma, it’s only PD-L1. But in a broader perspective, it’s PD-L1 and tumor mutational burden. But we do have a lot of indicators of whether a patient will respond or not. And I believe that these kind of signatures, for example, interferon gamma signatures, which are a level of expression of inflammation in the tumor lesion will be important...
Yeah, I’m sure that we will see even more biomarkers. At this time point, it’s actually very few which are in clinical practice. For melanoma, it’s only PD-L1. But in a broader perspective, it’s PD-L1 and tumor mutational burden. But we do have a lot of indicators of whether a patient will respond or not. And I believe that these kind of signatures, for example, interferon gamma signatures, which are a level of expression of inflammation in the tumor lesion will be important. But also, I would say that we could also look into more of the genomic profile of the cells and of the tumor microenvironment. And here we had a presentation at a late-breaking abstract by Mario Presti, who also looked into these kind of refractory mechanisms also for TIL therapy, which looked like what we have already seen for checkpoint inhibitors, that you have a downregulation of all these immune-supporting pathways during this refractory development.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
